Nimenrix Injection

Meningococcal polysaccharide groups A C Y and W-135 conjugate vaccine

0.5 ml/prefilled syringe

Radiant Pharmaceutical Ltd.

Pack size	0.5 ml
Dispensing mode
Source
Agent
Retail Price	4500.00 AED

Indications

Nimenrix Injection is used for: To prevent invasive, meningococcal disease

Adult Dose

Meningococcal Vaccination Indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y. Primary immunisation Infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses. Infants from 6 months of age, children, adolescents and adults: a single 0.5 mL dose should be administered. An additional primary dose of this vaccine may be considered appropriate for some individuals. Booster doses Long-term antibody persistence data following vaccination with Nimenrix are available up to 10 years after vaccination. After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last vaccination. In previously vaccinated individuals 12 months of age and older, This vaccine may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine.

Child Dose

Meningococcal Vaccination Indicated active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in high risk adults Primary immunisation Infants from 6 weeks to less than 6 months of age: two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses. Infants from 6 months of age, children, and adolescents: a single 0.5 mL dose should be administered. An additional primary dose may be considered appropriate for some individuals. Booster doses after completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last vaccination. In previously vaccinated individuals 12 months of age and older, Nimenrix may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine.

Renal Dose

Administration

IM Administration Immunisation should be carried out by intramuscular injection only. In infants, the recommended injection site is the anterolateral aspect of the thigh. In individuals from 1 year of age, the recommended injection site is the anterolateral aspect of the thigh or the deltoid muscle

Contra Indications

Hypersensitivity to the vaccine or after previous inj. Postpone vaccination in case of moderate or severe febrile or acute disease.

Precautions

Not to be inj intravascularly, intradermally or SC. Not a substitute for tetanus immunization. Postpone vaccination in subjects w/ acute severe febrile illness. Thrombocytopenia or any coagulation disorder; syncope; anatomic or functional asplenia eg, sickle cell disease. Patients receiving immunosuppressants or w/ immunodeficiency; complement deficiencies & receiving treatment inhibiting terminal complement activation eg, eculizumab. Avoid injury from faints. Pregnancy & lactation.

Pregnancy-Lactation

Pregnancy There is limited experience with the use of this vaccine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryo/fetal development, parturition or post-natal development (see section 5.3). This vaccine should be used during pregnancy only when clearly needed, and the possible advantages outweigh the potential risks for the fetus. Breast-feeding It is unknown whether this vaccine is excreted in human milk. Nimenrix should only be used during breastfeeding when the possible advantages outweigh the potential risks. Fertility Animal studies do not indicate direct or indirect harmful effects with respect to fertility.

Interactions

Reduced immune response w/ immunosuppressive therapies eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids.

Adverse Effects

Side effects of Meningococcal polysaccharide groups A C Y and W-135 conjugate vaccine : >10% Tenderness at injection site Erythema Swelling Irritability Abnormal crying Drowsiness Appetite loss Induration Vomiting Fever Malaise Headache

Mechanism of Action

Anti-capsular meningococcal antibodies protect against meningococcal diseases via complement-mediated bactericidal killing. This vaccine induces the production of bactericidal antibodies against capsular polysaccharides of Neisseria meningitidis groups A, C, W-135 and Y when measured by assays using either rabbit complement (rSBA) or human complement (hSBA). By conjugating capsular polysaccharide to a protein carrier that contains T-cell epitopes, meningococcal conjugate vaccines like NIMENRIX change the nature of the immune response to capsular polysaccharide from T-cell independent to T-cell dependent.

Note

Nimenrix 0.5 ml/prefilled syringe Injection manufactured by Radiant Pharmaceutical Ltd.. Its generic name is Meningococcal polysaccharide groups A C Y and W-135 conjugate vaccine. Nimenrix is availble in Bangladesh. Farmaco BD drug index information on Nimenrix Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.